Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: In their meta-analysis, Dr Dale and colleagues1 stratified cancer risk associated with statin use according to the hydrophilicity or lipophilicity of the individual drugs. This physicochemical property affects uptake of a particular statin by extrahepatic cells, including malignant cells, in which it can inhibit cell growth by down-regulating the synthesis of mevalonate.2 In interpreting this study, there are 2 points that should be addressed.
Duncan RE, El-Sohemy A, Archer MC. Statins and the Risk of Cancer. JAMA. 2006;295(23):2720-2722. doi:10.1001/jama.295.23.2720-a